Field

Modality

Supply services of API, intermediates and building blocks   related to small molecule drug for human use 

Traditional   small molecule drugs (containing impurities); Small molecule conjugate drugs,   such as PROTAC, molecular glue, smDC, etc.; natural products; Various small   molecule building blocks, such as amino acids, oligonucleotides,   fluorides-containing compounds, boron-containing compounds,   silicon-containing compounds, isotope markers such as deuterated compounds,   etc.

Table 1.2, Module 2

Field

Modality

Supply services of drug substance and building blocks related to   macromolecular drug use

Peptides,   monoclonal antibodies, bispecific antibodies, recombinant proteins, various   conjugate drugs XDC such as ADC and PDC, oligonucleotide drugs such as siRNA, saRNA, ASO, Aptamer, etc., and various related macromolecular   building blocks.

Table 1.3, Module 3

Field

Modality

Supply service of small molecule and macromolecule product  related to non-human drug use

Pesticides,   veterinary drugs, flavors and fragrances, food and feed additives, materials   in the field of new energy, materials in the field of semiconductors and   chips, molecular probes, diagnostic reagents, etc.

Table 1.4, Module 4

Field

Services

Technical consulting and management service

1）Generic drug development: covering a wide range of disease   areas, such as kidney disease, psoriasis, cardiovascular disease, cancer, and   etc.; The molecular entities are mainly small molecule drugs, including   peptides; The specific business includes drug R&D project consulting, CMC   strategy formulation and execution, API and drug product development related   technology consulting, registration affair, and etc.

2）Biosimilar: involving a wide   range of disease fields, covering ophthalmic diseases, respiratory diseases,   orthopedic diseases, nervous system diseases, immune system diseases,   cardiovascular diseases, cancer, and etc.; Molecular entities are diverse, including   monoclonal antibodies, bispecific antibodies, recombinant proteins, XDCs,   oligonucleotides, and etc. The specific business includes R&D project   initiation consultation, CMC strategy formulation and execution, drug   substance and drug product related technology consultation, registration   affair, and etc.

3）Innovative drug development   (small and large molecules): covering a wide range of disease areas;   Molecular entities can range from small molecules to large molecule drugs;   The specific business includes R&D project consultation, molecular   design, CMC strategy formulation and execution, CMC technology development,   CMC registration affair, and etc.

4）Small molecule and   macromolecule product development: Process development and analytical   development related to various small molecules and macromolecules, including   the products listed we herein, are suitable for scenarios such as small-scale   laboratory and even commercial production.

Module 1

1）Available from   gram to 100 kg

2）Good and consistent product quality

3）Competitive product price and sustainable product supply

Module 2

1) Available from microgram to gram level

2) Good and consistent   product quality

3) Competitive price and   sustainable product supply

Module 3

1）Available from   microgram level, to gram level, to kilogram level, to 100 kilogram level

2）Good and consistent product quality

3）Competitive product price and sustainable product supply

Module 4

1）Generic drugs and biosimilar   development consulting service: low cost, high efficient, fast and superior   quality delivery e.g. comparable product quality profile 

2）Innovative drugs development consulting service: fast and   superior delivery of project inanition consulting: unique innovation,   forward-looking, differentiation, feasible protocol and competitive marketing   advantage; full lifecycle CMC and regulatory affair consulting service   enables the success of new drug development at different stages ranging from   drug discovery to IND, clinical study and NDA/BLA stage.

3）Small and large molecule process development consulting   service: Low cost, environment friendly, safe, easy to scale up for the   process developed; process suitable for laboratory scale, pilot plant   scale,  and commercial plant scale   under the circumstance of nonGMP and cGMP environment.

4）Molecular entities are diverse, including small molecules,   monoclonal antibodies, bispecific antibodies, fusion proteins,   oligonucleotides, various drug conjugates, and etc..